Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to 19.51%.

  • Mimedx's EBITDA Margin rose 62300.0% to 19.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.69%, marking a year-over-year decrease of 47700.0%. This contributed to the annual value of 16.87% for FY2024, which is 53300.0% up from last year.
  • Mimedx's EBITDA Margin amounted to 19.51% in Q3 2025, which was up 62300.0% from 12.55% recorded in Q2 2025.
  • Mimedx's EBITDA Margin's 5-year high stood at 26.89% during Q2 2024, with a 5-year trough of 15.79% in Q1 2022.
  • Over the past 5 years, Mimedx's median EBITDA Margin value was 11.9% (recorded in 2024), while the average stood at 6.14%.
  • As far as peak fluctuations go, Mimedx's EBITDA Margin soared by 277500bps in 2023, and later tumbled by -143500bps in 2025.
  • Over the past 5 years, Mimedx's EBITDA Margin (Quarter) stood at 2.53% in 2021, then surged by 501bps to 15.21% in 2022, then increased by 17bps to 17.84% in 2023, then tumbled by -33bps to 11.9% in 2024, then surged by 64bps to 19.51% in 2025.
  • Its EBITDA Margin was 19.51% in Q3 2025, compared to 12.55% in Q2 2025 and 9.35% in Q1 2025.